Xiya Reagent:NovoEight® is approved by the US Food and Drug Admi

About NovoEight®

NovoEight® is approved by the US Food and Drug Administration (October 2013) and the European Medicines Agency (November 2013) for the treatment and prophylaxis of bleeding in patients with haemophilia A. NovoEight® is also approved in Japan (January 2014), Australia (January 2014), and Switzerland (February 2014), and applications for regulatory approvals have been submitted in a range of other countries.

About guardian(TM)

The pivotal guardian(TM) clinical programme is one of the largest and most comprehensive preregistration clinical trial programmes in haemophilia, with more than 210 patients with severe haemophilia A treated. The guardian(TM)2 trial is an extension of the clinical programme. The post hoc analysis of the guardian(TM)2 trial involved 166 patients who had participated in guardian(TM)2 and either guardian(TM)1 or 3, had <=1 week of surgery treatment in guardian(TM)1 or 3 (initial period), and had =>3 months of exposure to turoctocog alfa prophylaxis during a selected time period (1 January 2012-30 June 2013) in guardian(TM)2.

About Haemophilia A

Haemophilia is a chronic, inherited bleeding disorder that primarily affects males. People with haemophilia A are either missing or have a malfunctioning factor VIII protein, which is essential for proper blood clotting. People with haemophilia A have a tendency to bleed longer than most or to bleed internally into muscles, joints or organs because they are missing this clotting factor. To manage the disease and stop bleeding, people with haemophilia A must replace the missing factor VIII protein, which is accomplished by intravenous injection of the clotting factor.5

Globally, it is estimated that more than 400,000 people have haemophilia.6 The disease is severely underdiagnosed in developing countries.· 以上资料由西亚试剂：http://www.xiyashiji.com/ 提供此产品的详细信息如密度,含量,分子式,分子量等均可在西亚官网查询